The next trick: pulling coronavirus out of thin air

Thermo Fisher Scientific
Thursday, 01 July, 2021


The next trick: pulling coronavirus out of thin air

A decade ago, when John Burke earned his master’s degree in healthcare emergency management, he wrote his thesis on pandemic planning. So when the coronavirus hit last spring, Burke, the fire chief in Sandwich, Massachusetts, was ready.

“I had my playbook ready to go,” Burke said.

Testing for the virus was a top priority, so he connected with a private laboratory to ensure that his firefighters, who were transporting coronavirus patients to hospitals, could be regularly tested.

And then he heard that Thermo Fisher Scientific has an air sampler, AerosolSense Sampler, that could help him detect airborne coronavirus particles.

By December, he had installed one in a fire station hallway. The device, about the size of a toaster oven, sucked in ambient air and trapped airborne virus particles — if there were any to be found — in a specialised cartridge. Each afternoon, an employee would remove the cartridge and walk it to the UPS drop box across the street, sending it off for laboratory analysis.

Before the month was out, the air sampler had turned up traces of the virus. Officials ultimately traced it back to a town employee who had been working in the station, without a mask, during a quiet holiday period.

Thermo Fisher Scientific’s AerosolSense Sampler can be used to detect a variety of airborne pathogens, including the coronavirus. It can be deployed in hospitals, nursing homes, offices, schools and other buildings to monitor for signs of the virus as society begins to reopen.

“I’m not sure that there’s anything else on the market that’s as easy to use,” said Linsey Marr, an expert in airborne viruses at Virginia Tech. “This will enable collection of air samples by almost anyone.”

The approach has real potential, experts say. But it also raises a thicket of logistical questions, they add, and must be deployed carefully, with a clear understanding of what the technology can and cannot do.

Air samplers are already widely used to detect a variety of pollutants. But capturing airborne viruses is considerably more difficult. Viral aerosols are tiny and compose just a small fraction of the detritus that floats around in the air.

“You’re looking for a needle in a haystack in a field of haystacks,” Dr Marr said.

The AerosolSense sampler was designed to be easy to use. The device draws air into a collection pipe and directs it toward a replaceable, cylindrical cartridge. The cartridge, which is about the size of a 10 mL syringe, contains a proprietary foam-like substance that traps viral particles.

After a few hours, or longer, the cartridge can be pulled out of the machine and sent to a lab for analysis. Technicians can use PCR, the polymerase chain reaction technique that underlies the gold-standard test for COVID-19, to determine whether genetic material from the coronavirus is present.

Results can take up to 24 hours if the cartridge has to be sent to a third-party laboratory, but hospitals, universities and nursing homes that have labs on site can process the cartridges within a few hours, Thermo Fisher Scientific says.

The company has also conducted ‘initial feasibility testing’ with a rapid PCR test that returns results in 30 minutes (the test is made by Mesa Biotech, which Thermo Fisher Scientific recently acquired).

A series of studies — performed in an enclosed box, a 9 x 14 ft room and the hospital rooms of COVID-19 patients — suggested that the AerosolSense sampler could capture the coronavirus even when present at low levels, said Kevin Van Den Wymelenberg, who conducted the research and directs the Biology and the Built Environment Center at the University of Oregon.

“We’re confident that this is sensitive enough to use in real-world environments with COVID-positive individuals,” he said.

Thermo Fisher Scientific also piloted the samplers in a COVID-19 field hospital in Worcester, Massachusetts. The hospital deployed the devices in patient care areas where the virus was expected to be found, and in staff break rooms where it was not.

“Our cold zones were indeed cold,” said Dr John Broach, an emergency physician at UMass Memorial Medical Center and the medical director of the field hospital. “And our hot zone had heavy contamination, which was expected.”

Thermo Fisher Scientific says healthcare facilities could use the samplers to make sure that their COVID protocols are working — and that the virus is not making its way out of patient rooms or through employees to multiple facilities.

“We see the facilities asking, are their scheduling and pre-screening activities effective?” said Mark Stevenson, Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific. “Are their cleaning and ventilation procedures adequate? And consequently, can I give my patients confidence in their visit to the facility?”

Of course, detecting the virus in the hospital room of a COVID-19 patient is one thing, said Alex Huffman, an aerosol scientist at the University of Denver: “It’s another step to go into an environment that likely has much lower concentrations still, surveilling a classroom or a medical clinic where you have no idea if there’s going to be somebody positive or not.”

And an air sampler is not a silver bullet, said Burke, who made sure that his employees continued to wear masks, socially distance and get regular COVID tests even after he installed the air sampler.

“It can’t be like a smoke detector in your house where you’re, like, ‘I’m just going to have the machine, I’m not going to do anything else, it will let me know when there’s a problem,’” he said.

There are not yet any truly autonomous viral samplers — humans are still required to remove and analyse the samples. That takes time — and means that the results provided by these samplers are not real-time snapshots but composite portraits of a building over the previous two or 12 or 24 hours. And although PCR analysis can reveal whether genetic material from the coronavirus is present, it cannot distinguish between intact, infectious virus and viral fragments that pose no risk.

None of these drawbacks are deal-breakers, said Dr Marr, who noted that it was still useful to know whether airborne coronavirus particles were in a space recently.

“If they’ve detected it in air, then it’s probably fairly freshly emitted,” she said. “And I’d be willing to bet that there is some infectious virus in there.”

But the results need to be interpreted with care. A negative result does not mean that there is no virus present — simply that the air sampler did not collect any.

Figuring out how to respond to a positive sample might prove even trickier. “I don’t think the answer is just evacuate the building,” Dr Van Den Wymelenberg said.

One approach might be to use air sampling for larger-scale surveillance. If public health authorities see a spike in viral levels in a certain region or neighborhood, this could be an early warning sign that a surge of new COVID-19 cases is coming — and that officials need to step up their testing and contact tracing.

Easily available, user-friendly air samplers could also make it possible for more scientists to conduct research on viral aerosols, Dr Huffman said.

“In the medium and long term, I think technology like this has a tremendous role to play in continuing to push forward the state of knowledge about these things such that we can make better decisions that help with other viral aerosols, like influenza and the next pandemic that comes along,” he said. “That’s not to say it can’t help now, but I think its real influence may be even greater as we go further and further into the future.”

Contact a specialist about how you can use the AerosolSense Sampler in your facility.

Learn more: https://www.thermofisher.com/au/en/home/industrial/environmental/in-air-pathogen-surveillance.html.

Image credit: ©stock.adobe.com/au/janonkas

Related Sponsored Contents

Overcoming clinical trial complexities with efficient data management

Clinical trials are becoming more complex, potentially leading to lower performance, higher...

Tech partnerships: working together to unlock healthcare potential

The real and lasting value of a tech partner and how purpose-built software optimises operations...

Beyond IT: Cybersecurity awareness in healthcare, a shared responsibility

Nam Lam, Managing Director ANZ at SailPoint, shares insights on the increasing threat of...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd